Nanjing Leads

Leads Biolabs is a clinical-stage biotechnology company headquartered in Nanjing, China, dedicated to the discovery and development of innovative antibody-based therapeutics for oncology. The company leverages its proprietary technology platforms, including the M-Body and V-Body systems, to develop a diverse pipeline of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Its lead candidate, LBL-007, is a LAG-3 antagonist currently in Phase 2 clinical trials for various solid tumors. Leads Biolabs maintains a global presence with research and development facilities in both China and the United States. The company focuses on high-potential targets such as CD47, PD-L1/4-1BB, and TNFR2 to address significant unmet medical needs in cancer immunotherapy. Through strategic partnerships and internal innovation, Leads Biolabs aims to provide effective and affordable treatment options for patients worldwide.